Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Summary by targetedonc.com
The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

2 Articles

targetedonc.comtargetedonc.com

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.

Read Full Article
curetoday.comcuretoday.com

FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

curetoday.com broke the news in on Thursday, January 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal